Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;9(2):68-74.
doi: 10.1177/1758834016675099. Epub 2016 Nov 2.

Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens

Pei-Jian Peng  1 , Bao-Jun Lv  2 , Zhi-Hui Wang  1 , Hai Liao  3 , Yu-Meng Liu  4 , Zhong Lin  1 , Yun-Yan Con  1 , Pei-Yu Huang  5
Affiliations

Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens

Pei-Jian Peng et al. Ther Adv Med Oncol. 2017 Feb.

Abstract

Background: In this multi-institutional prospective study, we aimed to assess the safety and efficacy of nedaplatin plus S-1 (NS) chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when platinum-containing regimens failed.

Methods: A total of 52 recurrent and metastatic NPC patients who previously received, but failed with platinum-containing chemotherapy, had oral S-1 chemotherapy (twice daily from the first day to the fourteenth day) and nedaplatin (80 mg/ m2, day 1) every 3 weeks. The body surface area (BSA) decided the dose of S-1: 40 mg twice a day when BSA < 1.25 m2; 50 mg twice daily when 1.25 m2 ⩽ BSA < 1.5 m2; and 60 mg twice daily when BSA ⩾ 1.5 m2.

Results: Treatment was well tolerated. The main hematological adverse event was neutropenia. Five patients (9.6%) had grade 3 neutropenia. Three patients were found with grade 3 anemia (5.8%). One patient was found with grade 3 thrombocytopenia (1.9%). No patient was found with grade 3 or 4 nonhematological toxicity. The rates of complete response, partial response and overall response were 3.8%, 38.5% and 42.3%, respectively. Median time to progression was 6.2 months and median survival was 14.6 months. The rates of 1-year survival and 2-year survival were 63% and 27%, respectively.

Conclusions: NS chemotherapy provides a satisfactory and safe clinical activity for patients with recurrent and metastatic NPC after platinum-containing chemotherapy failed.

Keywords: S-1; chemotherapy; nasopharyngeal carcinoma; nedaplatin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Kaplan–Meier Curve of progression-free survival.
Figure 2.
Figure 2.
Kaplan–Meier Curve of overall survival.
See this image and copyright information in PMC

References

    1. Alberts D., Fanta P., Running K., Adair L., Jr., Garcia D., Liu-Stevens R., et al. (1997) In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 39: 493–497. - PubMed
    1. Au E., Ang P. (1994) A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 5: 87–89. - PubMed
    1. Cao S., Simons M., Qian C. (2011) The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J cancer 30: 114–119. - PMC - PubMed
    1. Cunningham D., Coleman R. (2001) New options for outpatient chemotherapy—the role of oral fluoropyrimidines. Cancer Treat Rev 27: 211–220. - PubMed
    1. Fandi A., Bachouchi M., Azli N., Taamma A., Boussen H., Wibault P., et al. (2000) Long-term disease-free survivors in metastatic undifferentiated carcinoma of the nasopharyngeal type. J Clin Oncol 18: 1324–1330. - PubMed

LinkOut - more resources